|
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen |
Research Funding - AstraZeneca/MedImmune; Roche/Genentech |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech |
|
|
Honoraria - Merck Sharp & Dohme; Sanofi/Aventis |
Consulting or Advisory Role - Janssen Oncology; Lilly |
Research Funding - Kura Oncology; Ono Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Merck; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi |
(OPTIONAL) Uncompensated Relationships - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Pfizer; Roche |
|
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst) |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Incyte; Medscape; Merck; MSD; Pfizer; Roche; Roche/Genentech; UroToday |
|
|
Stock and Other Ownership Interests - Rainier Therapeutics |
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre |
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Algeta/Bayer; AstraZeneca; AstraZeneca/MedImmune; Dendreon; EMD Serono; Janssen Biotech; Sanofi |
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen-Ortho |
Travel, Accommodations, Expenses - Algeta/Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma |
Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst) |
Expert Testimony - Celgene; sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen |
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst) |